The Center for Biosimilars® recaps the top news for the week of May 27, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 27.
Number 5: New bipartisan legislation has been introduced to promote biosimilar education.
Number 4: The Senate Committee on Health, Education, Labor, and Pensions released draft legislation aimed at lowering the cost of healthcare in the United States.
Number 3: A new Federal Trade Commission report found that fewer drug patent settlements include provisions that are likely to be anticompetitive.
Number 2: UnitedHealthcare announced that it will prefer the use of brand-name pegfilgrastim, Neulasta, over biosimilar options.
Number 1: Officials in British Columbia announced that many patients currently taking reference biologics will be switched to biosimilars within 6 months.
Finally, last week, our e-newsletter asked how important you think factors like on-body injection or reduced administration of growth factors are to biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.